Erythropoietin Drugs Market to Witness Growth by 2028 | Key Companies - ROCHE DIAGNOSTICS, HOSPIRA INC., CELLTRION, INC, INTAS PHARMACEUTICALS, TEVA PHARMACEUTICAL INDUSTRIES LTD

How big is the erythropoietin drug market?

As per the report published by Allied Market Research, the global Erythropoietin Drugs Market was pegged at $9.24 billion in 2020, and is estimated to reach $14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028.

The global erythropoietin drugs market has experienced steady growth over the years, driven by the increasing prevalence of chronic kidney disease, cancer, and other conditions associated with anemia. Additionally, advancements in biotechnology and the development of novel EPO drugs have contributed to market expansion.

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/59

Key Takeaways:

Market Growth and Size: The EPO drugs market has historically experienced significant growth due to the rising prevalence of anemia in various patient populations, including those with chronic kidney disease, cancer, and certain other chronic conditions.

Biopharmaceutical Companies: Several pharmaceutical companies are prominent players in the EPO drugs market. These include Amgen (Epoetin alfa), Johnson & Johnson (Epogen), and Roche (Mircera), among others. Biosimilars, which are comparable versions of existing biologic drugs, have also been introduced by various companies, contributing to market competition.

Therapeutic Applications: EPO drugs are primarily used to treat anemia caused by reduced red blood cell production, such as in chronic kidney disease patients undergoing dialysis, cancer patients undergoing chemotherapy, and individuals with HIV/AIDS-related anemia.

Regulatory Landscape: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have guidelines and regulations in place for the approval and monitoring of EPO drugs and biosimilars.

Biosimilars Impact: The introduction of biosimilars has led to increased competition in the EPO drugs market, potentially resulting in cost savings for patients and healthcare systems.

Covid-19 scenario:

The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shutdown temporarily.

However, the pandemic had a positive effect on the demand for medical services including erythropoietin.

As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.

Request for Customization - https://www.alliedmarketresearch.com/request-for-customization/59

Market Segmentation:

Type of EPO Drug:

Epoetin Alfa: This is one of the most well-known and widely used forms of EPO. It's used to treat anemia in patients with chronic kidney disease, cancer, and other conditions.

Darbepoetin Alfa: This is a newer form of EPO that has a longer half-life than epoetin alfa. It's also used to treat anemia in similar patient populations.
Therapeutic Application:

Chronic Kidney Disease-Related Anemia: EPO drugs are commonly used to treat anemia in patients with chronic kidney disease, especially those undergoing dialysis.

Cancer-Related Anemia: Cancer patients undergoing chemotherapy often develop anemia, and EPO drugs can help manage this condition.

HIV/AIDS-Related Anemia: EPO drugs can be used to treat anemia in patients with HIV/AIDS.

Other Conditions: Research has explored the use of EPO drugs in various other conditions, including neuroprotection after stroke and traumatic brain injury.

Distribution Channel:

Hospital Pharmacies: EPO drugs are often dispensed through hospital pharmacies, especially for patients undergoing dialysis or cancer treatment.

Retail Pharmacies: Some EPO drugs may also be available through retail pharmacies, particularly for patients who are not undergoing intensive medical treatments.

Geography:

Regional Markets: The EPO drugs market can be segmented based on regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Different regions may have varying prevalence rates of anemia and access to healthcare.

End Users:

Hospitals and Clinics: EPO drugs are frequently administered in hospital settings, particularly for patients undergoing dialysis or cancer treatment.
Ambulatory Surgical Centers: Some EPO drugs may also be administered in ambulatory surgical centers, especially for patients undergoing less intensive medical procedures.

Procure Complete Report at 20% Discount (258 Pages):

https://www.alliedmarketresearch.com/purchase-enquiry/59

Table of Contents:

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Clinical trials for EPO drug
3.3.Market share analysis, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.4.1.2.Growing trends of commercialization for erythropoietin biosimilars
3.4.1.3.Increasing level of awareness about the benefits of EPO therapeutics

3.4.2.Restraints

3.4.2.1.Unaffordability of therapeutics
3.4.2.2.Longer duration of treatments
3.4.2.3.Adverse amount of side effects

Related Reports :

Exosome Diagnostic and Therapeutic Market https://www.alliedmarketresearch.com/exosome-diagnostic-and-therapeutic-market

Medical Aesthetic Devices Market https://www.alliedmarketresearch.com/medical-aesthetics-market

Surgical Navigation Systems Market https://www.alliedmarketresearch.com/surgical-navigation-systems-market

Dystonia Drugs Market https://www.alliedmarketresearch.com/dystonia-drugs-market-A13938

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.